Akron Children's Hospital > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Nexium in Pediatric Patients with Erosive Esophagitis

Safety and Efficacy of Nexium in Pediatric Patients with Erosive Esophagitis

Description:

The purpose of this study is to look at the use of Nexium in helping to heal Erosive Esophagitis (EE), which is irritation in the pipe that carries food from your mouth to your stomach. This study will look at children aged 1-11 years old.

Who May Qualify?:

Patients:

Age 1-11 years old
With at least a 3-month history of GERD
With confirmed presence of EE at time of endoscopy
Weighing greater than or equal to 10 kg (22 lbs)

Who Does Not Qualify:

Patients:

Requiring surgery during the study period
With a significant clinical illness within 4 weeks prior to the start of treatment
With a hypersensitivity to Nexium or any other PPI
Less than 1 or greater than 11 years old

Interested in participating?

We are currently recruiting

Study Sponsor:

AstraZeneca

Full IRB Study Title:

A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age

IRB Study ID:

2022-037

If you are interested in this study or have questions about your child's eligibility, please contact:

Merry Tomcany, mtomcany@akronchildrens.org, 330-543-4616

Lead Investigator